Segulah's CCS Healthcare acquires Propyless

Merck Sharp & Dohme is rationalising the number of production facilities within the group. In connection with the closing of a factory plant a few years ago and the internationalisation of its production, the global pharmaceutical company had been looking to divest Propyless in order to keep the product rooted in the Swedish market.

The parties had been engaged in a lengthy dialogue regarding a possible deal. Propyless complements CCS's pharmaceutical and skin care products, and fits the company's growth strategy, according to CCS. As a new owner CCS Healthcare will now seek to develop the product type further.

Based in Borlänge, Sweden, CCS is a manufacturer and distributor of personal care and healthcare products, focused on skin care, pharmaceuticals and dental hygiene. It is also active within the disinfection segment in Sweden and Norway with its brands Dax and Antibac. CCS has a turnover of close to SEK 500m.

Company
Introduced in the late 1980s as a registered trademark in the Swedish market and based in Malmö, Propyless is a lotion based on propylene glycol. The product is used for dry skin, atopic dermatitis and psoriasis.

People
Christian Tegenmark, Christian Sievert and Nikolay Bogdanov worked on the deal for Segulah. Jonas Nilsson is the CEO of CCS.

Advisers
Equity - Nord & Co. - (Legal)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Portfolio management
• Consumer
• Sweden
• Segulah